Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, summarises the KEYNOTE-716 trial (NCT03553836) comparing pembrolizumab to placebo for high-risk melanoma. Treatment with pembrolizumab resulted in a 35% reduction in risk of recurrence compared to placebo. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
![Почувствуй себя богом, или Моделирование жизни на Java. Часть I [GeekBrains]](http://i.ytimg.com/vi/lmaB4I1qnB0/mqdefault.jpg)
![Почувствуй себя богом, или Моделирование жизни на Java. Часть I [GeekBrains]](https://i.ytimg.com/vi/lmaB4I1qnB0/mqdefault.jpg)
![[1ª AT] #178: Chronology of Idents from ABC (1942 - 2024)](https://i.ytimg.com/vi/b6M96H2bezA/mqdefault.jpg)
